Publication: The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
Repository URI
Publisher DOI
10.3389/fonc.2021.796317
Date
2022-01-13
Type
Article
Authors
Hussien, Nervana
Hussien, Rasha S.
Saad, Darine Helmy Amin
El Kassas, Mohamed
Mai Ezz El Din
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers
Publisher DOI
Source
https://www.frontiersin.org/articles/10.3389/fonc.2021.796317/full
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Borderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat difficult to assess by current radiological parameters.
Aim: To evaluate the role of Magnetic Resonance Imaging (MRI) pancreatic protocol, including Diffusion-Weighted Imaging (DWI), in patients with BRPC receiving neoadjuvant therapy, and further compare it to RECIST criteria and outcome.
Methods: Histologically confirmed BRPC patients were prospectively included. DWI-MRI was performed pre- and post-therapy. Clinical characteristics with ensuing operability were recorded and correlated to radiological RECIST/apparent diffusion coefficient (ADC) change, preoperative therapy administrated, surgical resection status, and survival.
Results: Out of 30 BRPC cases, only 11 (36.7%) ultimately underwent pancreaticoduodenectomy. Attaining a stationary or stable disease via ADC/RECIST was achieved in the majority of cases (60%/53.3% respectively). Of the 12 patients (40%) who achieved a regression by ADC, 11 underwent surgery with an R0 status. These surgical cases showed variable RECIST responses (PR=5, SD=4, PD=3). Responders by ADC to neoadjuvant therapy were significantly associated to presenting with abdominal pain (p =0.07), a decline in post-therapy CA19-9 (p<0.001), going through surgery (p<0.001), and even achieving better survival (p<0.001 vs. 0.66).
Conclusion: DWI-MRI ADC picked up patients most likely to undergo a successful operative procedure better than traditional RECIST criteria. An algorithm incorporating novel radiological advances with CA19-9 deserves further assessment in future studies.
Description
Keywords
RECIST criteria, radiological assessment, ADC, DWI-MRI, borderline resectable pancreatic cancer
Citation
Hussien N, Hussien RS, Saad DHA, El Kassas M, Elkhatib WF and Ezz El Din M (2022) The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer. Front. Oncol. 11:796317. doi: 10.3389/fonc.2021.796317
Journal Title
Frontiers in Oncology
Journal Title
Journal Title
Volume
11
Issue
Volume
Collections
© 2023 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.